AnaptysBio (NASDAQ:ANAB) Shares Down 5.7% - Should You Sell?

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report)'s stock price fell 5.7% during mid-day trading on Tuesday . The company traded as low as $19.80 and last traded at $20.02. 174,378 shares were traded during mid-day trading, a decline of 85% from the average session volume of 1,165,128 shares. The stock had previously closed at $21.22.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Wells Fargo & Company raised their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. BTIG Research downgraded shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday, December 2nd. UBS Group raised their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. Truist Financial reduced their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a research report on Wednesday, December 18th. Finally, Guggenheim reduced their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.45.

AnaptysBio Stock Down 1.3 %

The firm has a fifty day moving average of $15.81 and a 200-day moving average of $25.36. The stock has a market capitalization of $566.55 million and a price-to-earnings ratio of -3.06.

Insider Buying and Selling

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 6,646 shares of the stock in a transaction dated Thursday, January 2nd. The shares were acquired at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the transaction, the director now directly owns 7,880,094 shares of the company's stock, valued at $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 33.70% of the stock is currently owned by insiders.

Institutional Trading of AnaptysBio

Several large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its stake in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in AnaptysBio in the 4th quarter valued at about $40,000. Values First Advisors Inc. purchased a new position in AnaptysBio in the 3rd quarter valued at about $49,000. AlphaQuest LLC lifted its holdings in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 4,237 shares in the last quarter. Finally, Virtus ETF Advisers LLC lifted its holdings in AnaptysBio by 24.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 936 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.